SCOPUS 정보 검색 플랫폼

Volumn 32, Issue 30, 2014, Pages 3454-

Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: A potential comparison bias

(3) Arcangeli, Stefano a De Bari, Berardino b Alongi, Filippo c

a SAN CAMILLO FORLANINI HOSPITAL (Italy)

b LAUSANNE UNIVERSITY HOSPITAL (Switzerland)

c SACRO CUORE DON CALABRIA HOSPITAL (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LETTER; LOW RISK PATIENT; MALE; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIATION SAFETY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84908439870 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2014.56.3213 Document Type: Letter

Times cited : (7)

References (7)

1
- 84880432474
- Radiation Therapy Oncology Group: Adverse event and safety information. http://www.rtog.org/ResearchAssociates/AdverseEventReporting.aspx
- Radiation Therapy Oncology Group: Adverse Event and Safety Information

2
- 84883053978
- National Cancer Institute: Common Terminology Criteria for Adverse Events (version 4.0). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-Quick Reference-8.5x11.pdf
- National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.0

3
- 84870946305
- Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide
- Axcrona K, Aaltomaa S, da Silva CM, et al: Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide. BJU Int 110:1721-1728, 2012
- (2012) BJU Int , vol.110 , pp. 1721-1728
- Axcrona, K.¹ Aaltomaa, S.² Da Silva, C.M.³

4
- 81855203431
- Stereotactic body radiotherapy (sbrt) for operable stage i non-small-cell lung cancer can sbrt be comparable to surgery?
- Onishi H, Shirato H, Nagata Y, et al: Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81:1352-1358, 2011
- (2011) Int J Radiat Oncol Biol Phys , vol.81 , pp. 1352-1358
- Onishi, H.¹ Shirato, H.² Nagata, Y.³

5
- 84865270338
- Review and uses of stereotactic body radiation therapy for oligometastases
- Alongi F, Arcangeli S, Filippi AR, et al: Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist 17:1100-1107, 2012
- (2012) Oncologist , vol.17 , pp. 1100-1107
- Alongi, F.¹ Arcangeli, S.² Filippi, A.R.³

6
- 77955927836
- Dose gradient near target-normal structure interface for nonisocentric cyberknife and isocentric intensity-modulated body radiotherapy for prostate cancer
- Hossain S, Xia P, Huang K, et al: Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78:58-63, 2010
- (2010) Int J Radiat Oncol Biol Phys , vol.78 , pp. 58-63
- Hossain, S.¹ Xia, P.² Huang, K.³

7
- 84866483298
- Will sbrt replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review
- Arcangeli S, Scorsetti M, Alongi F: Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 84:101-108, 2012
- (2012) Crit Rev Oncol Hematol , vol.84 , pp. 101-108
- Arcangeli, S.¹ Scorsetti, M.² Alongi, F.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.